Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 102

1.

The Effect of Phosphodiesterase 5 Inhibitor on Biochemical Recurrence Following Radical Prostatectomy in Patients with Prostate Cancer.

Chung JW, Kim JW, Ha YS, Choi SH, Lee JN, Kim BS, Kim HT, Yoo ES, Kwon TG, Kim TH.

Urol J. 2019 Jun 17;16(3):255-259. doi: 10.22037/uj.v16i3.4263.

2.

Phosphodiesterase Type 5 Inhibitor Use Following Radical Prostatectomy is not Associated with an Increased Risk of Biochemical Recurrence.

Jo JK, Kim K, Lee SE, Lee JK, Byun SS, Hong SK.

Ann Surg Oncol. 2016 May;23(5):1760-7. doi: 10.1245/s10434-015-5059-1. Epub 2015 Dec 30.

PMID:
26717939
3.

Phosphodiesterase Type 5 Inhibitor Use and Disease Recurrence After Prostate Cancer Treatment.

Loeb S, Folkvaljon Y, Robinson D, Schlomm T, Garmo H, Stattin P.

Eur Urol. 2016 Nov;70(5):824-828. doi: 10.1016/j.eururo.2015.12.013. Epub 2015 Dec 29.

4.

Is there a relationship between phosphodiesterase type 5 inhibitors and biochemical recurrence after radical prostatectomy: a systematic review and meta-analysis.

He Q, Liao BH, Xiao KW, Zhou L, Feng SJ, Li H, Wang KJ.

Int Urol Nephrol. 2018 Dec;50(12):2113-2121. doi: 10.1007/s11255-018-1982-y. Epub 2018 Sep 19.

PMID:
30232722
5.

Let's rethinking about the safety of phosphodiesterase type 5 inhibitor in the patients with erectile dysfunction after radical prostatectomy.

Kim SJ, Kim JH, Chang HK, Kim KH.

J Exerc Rehabil. 2016 Jun 30;12(3):143-7. doi: 10.12965/jer.1632646.323. eCollection 2016 Jun. Review.

6.

Sexual Rehabilitation After Nerve-Sparing Radical Prostatectomy: Free-of-Charge Phosphodiesterase Type 5 Inhibitor Administration Improves Compliance to Treatment.

Siena G, Mari A, Canale A, Mondaini N, Chindemi A, Greco I, Saleh O, Serni S, Nicita G, Minervini A, Carini M.

J Sex Med. 2018 Feb;15(2):120-123. doi: 10.1016/j.jsxm.2017.12.011.

PMID:
29425663
7.

Long-term cancer control outcomes in patients with clinically high-risk prostate cancer treated with robot-assisted radical prostatectomy: results from a multi-institutional study of 1100 patients.

Abdollah F, Sood A, Sammon JD, Hsu L, Beyer B, Moschini M, Gandaglia G, Rogers CG, Haese A, Montorsi F, Graefen M, Briganti A, Menon M.

Eur Urol. 2015 Sep;68(3):497-505. doi: 10.1016/j.eururo.2015.06.020. Epub 2015 Jun 26.

PMID:
26119559
8.

Prediction of biochemical recurrence after radical prostatectomy with PI-RADS version 2 in prostate cancers: initial results.

Park SY, Oh YT, Jung DC, Cho NH, Choi YD, Rha KH, Hong SJ.

Eur Radiol. 2016 Aug;26(8):2502-9. doi: 10.1007/s00330-015-4077-5. Epub 2015 Nov 11.

PMID:
26560721
9.

Predicting participation in and successful outcome of a penile rehabilitation programme using a phosphodiesterase type 5 inhibitor with a vacuum erection device after radical prostatectomy.

Kimura M, Caso JR, Bañez LL, Koontz BF, Gerber L, Senocak C, Donatucci CF, Vujaskovic Z, Moul JW, Polascik TJ.

BJU Int. 2012 Dec;110(11 Pt C):E931-8. doi: 10.1111/j.1464-410X.2012.11168.x. Epub 2012 Apr 23.

10.

Clinical evaluation of a novel method for the measurement of prostate-specific antigen, AccuPSA(TM) , as a predictor of 5-year biochemical recurrence-free survival after radical prostatectomy: results of a pilot study.

Lepor H, Cheli CD, Thiel RP, Taneja SS, Laze J, Chan DW, Sokoll LJ, Mangold L, Partin AW.

BJU Int. 2012 Jun;109(12):1770-5. doi: 10.1111/j.1464-410X.2011.10568.x. Epub 2011 Oct 12.

11.

Prospective analysis of penile length changes after radical prostatectomy.

Berookhim BM, Nelson CJ, Kunzel B, Mulhall JP, Narus JB.

BJU Int. 2014 May;113(5b):E131-6. doi: 10.1111/bju.12443. Epub 2013 Dec 2.

12.

Association of Cigarette Smoking and Smoking Cessation with Biochemical Recurrence of Prostate Cancer in Patients Treated with Radical Prostatectomy.

Rieken M, Shariat SF, Kluth LA, Fajkovic H, Rink M, Karakiewicz PI, Seitz C, Briganti A, Rouprêt M, Loidl W, Trinh QD, Bachmann A, Pourmand G.

Eur Urol. 2015 Dec;68(6):949-56. doi: 10.1016/j.eururo.2015.05.038. Epub 2015 Jun 3.

PMID:
26050111
13.

Do Second Primary Cancers Affect the Risk of Biochemical Recurrence in Prostate Cancer Patients Undergoing Radical Prostatectomy? A Propensity Score-Matched Analysis.

Kang M, Jung JW, Oh JJ, Lee S, Hong SK, Lee SE, Byun SS.

Clin Genitourin Cancer. 2016 Aug;14(4):e363-9. doi: 10.1016/j.clgc.2016.03.003. Epub 2016 Mar 10.

PMID:
27105723
14.

Long-term cancer control outcomes in patients with biochemical recurrence and the impact of time from radical prostatectomy to biochemical recurrence.

Pompe RS, Gild P, Karakiewicz PI, Bock LP, Schlomm T, Steuber T, Graefen M, Huland H, Tian Z, Tilki D.

Prostate. 2018 Jun;78(9):676-681. doi: 10.1002/pros.23511. Epub 2018 Mar 23.

PMID:
29570821
15.

Hypertriglyceridemia is a potential preoperative predictor for biochemical recurrence after radical prostatectomy.

Kang M, Jeong CW, Ku JH, Kwak C, Kim HH.

PLoS One. 2015 Mar 24;10(3):e0122438. doi: 10.1371/journal.pone.0122438. eCollection 2015.

16.

Tertiary Gleason pattern in radical prostatectomy specimens is associated with worse outcomes than the next higher Gleason score group in localized prostate cancer.

Özsoy M, D'Andrea D, Moschini M, Foerster B, Abufaraj M, Mathieu R, Briganti A, Karakiewicz PI, Roupret M, Seitz C, Czech AK, Susani M, Shariat SF.

Urol Oncol. 2018 Apr;36(4):158.e1-158.e6. doi: 10.1016/j.urolonc.2017.12.003. Epub 2017 Dec 27.

PMID:
29288003
17.

A Detailed Analysis of the Association Between Postoperative Phosphodiesterase Type 5 Inhibitor Use and the Risk of Biochemical Recurrence After Radical Prostatectomy.

Gallina A, Bianchi M, Gandaglia G, Cucchiara V, Suardi N, Montorsi F, Briganti A.

Eur Urol. 2015 Nov;68(5):750-3. doi: 10.1016/j.eururo.2015.02.002. Epub 2015 Feb 17.

PMID:
25700565
18.

Prognostic Value of Biochemical Recurrence Following Treatment with Curative Intent for Prostate Cancer: A Systematic Review.

Van den Broeck T, van den Bergh RCN, Arfi N, Gross T, Moris L, Briers E, Cumberbatch M, De Santis M, Tilki D, Fanti S, Fossati N, Gillessen S, Grummet JP, Henry AM, Lardas M, Liew M, Rouvière O, Pecanka J, Mason MD, Schoots IG, van Der Kwast TH, van Der Poel HG, Wiegel T, Willemse PM, Yuan Y, Lam TB, Cornford P, Mottet N.

Eur Urol. 2019 Jun;75(6):967-987. doi: 10.1016/j.eururo.2018.10.011. Epub 2018 Oct 17. Review.

PMID:
30342843
19.
20.

Penile rehabilitation for postprostatectomy erectile dysfunction.

Philippou YA, Jung JH, Steggall MJ, O'Driscoll ST, Bakker CJ, Bodie JA, Dahm P.

Cochrane Database Syst Rev. 2018 Oct 23;10:CD012414. doi: 10.1002/14651858.CD012414.pub2.

PMID:
30352488

Supplemental Content

Support Center